ASX Announcement | 21 September 2020
Noxopharm Limited (ASX:NOX)

Noxopharm Corporate Presentation September 2020

Sydney 21 September 2020: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide to shareholders its updated corporate presentation for September 2020.

The presentation outlines the Company's:

- focus on the lead drug candidate, Veyonda®, and its potential as an immuno-oncology drug treatment based on its ability to convert tumours from 'cold' to 'hot' tumours
- proposed clinical trial program
- commercial strategy.

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-

About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com

Investor & Corporate enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries
Julia Maguire
The Capital Network

E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Noxopharm Limited (ASX:NOX)

Corporate Presentation September 2020

Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.



Presentation overview…

1. Who We Are
2. The Need we Aim to Fill
3. Veyonda® Explained
4. Our Business
5. Investment Case

1. Who we are

- **Australian clinical-stage drug development company**
- ASX: NOX **Healthcare** sector
- **Veyonda®** - a major commercial opportunity with 'blockbuster' potential as an **immuno-oncology (I-O) drug**
- Aiming to make **Veyonda®** a **cost-effective I-O therapy** in a market dominated by treatment costs typically between A$250,000 -$1M
- Seeking **'blockbuster' sales** from higher response rates and broader use across multiple cancer types

2. The need we aim to fill



Immuno-oncology (I-O) therapy has taken the oncology world by storm and is the future of cancer therapy

I-O therapy works on the principle of re-enabling the immune system to attack cancer cells

But … with only about 5% or less of patients across all forms of cancer responding to I-O therapy, major challenges remain before it benefits most cancer patients

2. The need we aim to fill

3 main forms of I-O therapy

	CAR-T cell therapy	Checkpoint inhibitors	Radiotherapy
Science	T-cells activated in lab against cancer cells. Re-injected IV	Removal of T-cell blocking (checkpoint) proteins	Activate T-cells in irradiated tumours → abscopal effect
Response rates	60-90%	10-30%	Extremely rare
Limitations	**Restricted to leukemias. Ineffective in solid cancers because T-cells cannot access tumours**	**Restricted to a few cancer types. Requires tumours to have active T-cells**	**Abscopal response dependent on activated T-cells accessing remote tumours**

2. The need we aim to fill

CAR-T cell therapy | Checkpoint inhibitors | Radiotherapy

The common link between all 3 forms of I-O therapy is that they are dependent on activated T-cells gaining access to tumours

Problem: the majority of human tumours avoid immune attack by expelling T-cells and then preventing their re-entry

Answer: the widely accepted answer is to remove the block to T-cell re-entry, allowing immune cells to repopulate tumours and result in tumour destruction

This is called ….. converting tumours from COLD to HOT

2. The need we aim to fill

- Converting tumours from COLD to HOT regarded as an essential prerequisite for lifting the response rate to I-O therapies
- Pre-clinical and clinical evidence points to Veyonda® being the breakthrough drug, with no known competitive products emerging
- Veyonda® + radiotherapy emerging as a novel and revolutionary form of I-O therapy with significant cost and safety advantages
- Veyonda® + immune checkpoint inhibitors also with blockbuster potential

2. The need we aim to fill



Current market for I-O therapies

= **~ US$30 billion p.a.** (2019)

Increasing the response rate to I-O therapy

by COLD to HOT conversion

projected to create a potential market of

>US$150 billion+ p.a.

Noxopharm sees Veyonda® as a 'breakthrough' drug filling the US$120 billion+ gap

3. Veyonda® Explained

The Veyonda® Journey so far



3. Veyonda® Explained

- Proprietary suppository formulation to deliver prolonged drug half-life
- Convenience and high treatment compliance
- High tolerability with very low level of adverse events
- Family of 10 PCT patent applications in 80 countries covering I-O use including with immune checkpoint inhibitors, external radiotherapy, intravenous radiotherapy, chemotherapy
- 2020 PCT patent application concerning treatment of septic shock including COVID-19 patients

A breakthrough technology Converting Cold Cancers

3. Veyonda® Explained

First-in-class anti-cancer drug with unique 3-step actions

inhibition of protein folding (disulfide-thiol exchange)

inhibition of sphingosine kinase activity (ceramide/sphingosine-1-phosphate ratio)

Oncotoxic



Immuno-oncology effects



COLD → HOT



Step 1

Kills cancer cells. Unique action sparing most healthy cells

Step 2

Activates cancer-fighting immune cells (T-cells)

Step 3

Enables cancer-fighting immune cells to enter tumour and kill remaining cancer cells

3. Veyonda® Explained

DARRT Novel and effective I-O therapy

Low-dose radiation to a single tumour activates immune cells inside that tumour

Veyonda® amplifies the immune response and then spreads it to other tumours



- Theoretically applicable to most forms of solid cancer
- No known competitive technologies

The breakthrough advantage of COLD to HOT

3. Veyonda® Explained

IONIC Partnering immune checkpoint inhibitors



Checkpoint inhibitors ineffective in COLD tumours because of lack of immune cells

By converting tumour to HOT, Veyonda provides the immune cells able to take advantage of removal of immune checkpoints

- Theoretically applicable to many forms of solid cancer
- Few competitive technologies

The breakthrough advantage of COLD to HOT

4. Our Business - Veyonda® and Oncology

Clinical objective

To develop Veyonda® + radiotherapy (DARRT therapy) as the most cost-effective, well-tolerated and readily accessible I-O therapy for a wide range of cancer types

Commercial objective

To provide comprehensive pre-clinical and clinical data packages that are compelling for 'blockbuster' trade deals

4. Our Business - Veyonda® and Oncology

Cost is major issue with current I-O therapies

Typical course of I-O treatment = **4x median US household annual income**

Low response rates and associated serious side-effects also major issues with current I-O therapies

Veyonda® offers major competitive advantages

4. Our Business - Veyonda® and Oncology

Veyonda® development program

Program	Indication	IND-enabling	Phase 1	Phase 2	Phase 3
DARRT	mCRPC	PRIORITY-1			
IONIC	Multiple	PRIORITY-2			
LuPIN	mCRPC				
CEP	Sarcoma				
NOXCOVID	COVID-19				

4. Our Business - Veyonda® and Oncology

DARRT and end-stage prostate cancer is our #1 priority program

Aimed at the largest sector in the oncology market

- End-stage cancer where treatment is limited to palliative care
- Little competition
- Multi-billion dollar market opportunity

Attractive form of anti-cancer therapy

- Well-tolerated, short-course of therapy in out-patient clinic
- Most common form of radiotherapy (= low cost, ready availability)

4. Our Business - Veyonda® and Oncology

DARRT: Seeking proof-of-principle in **end-stage prostate cancer**



Course of Disease and Treatment Journey for Stage I - IV Prostate Cancer

4. Our Business - Veyonda® and Oncology

DARRT: DARRT-1 Phase 1b study

25 men with end-stage prostate cancer who had stopped responding to treatment, with metastatic and progressive disease, and were considered to have limited life-spans

- Clear evidence of an I-O effect
- In 10 men, tumours had stopped growing or were reduced in size
- Meaningful pain reduction in many men
- Abscopal responses confirmed in 4 men*
- Treatment well tolerated

* First known demonstration of abscopal responses in prostate cancer in more than isolated cases

4. Our Business - Veyonda® and Oncology

DARRT: DARRT-2 Phase 2 study

- Parexel – a Top Global Clinical Research Organisation will implement the trial
- Multi-national
- Approximately 200 patients
- 1 cycle radiotherapy; 6 cycles of Veyonda® treatment
- Enrolment start early 2021
- Ongoing newsflow in connection with key milestones

  - US based
  - Extensive oncology experience

4. Our Business - Veyonda® and COVID-19

NOXCOVID: Phase 1 study

~40 COVID-19 patients hospitalised with moderate lung disease requiring supplementary oxygen. Objective is to prevent progression into a potentially catastrophic cytokine storm and septic shock

- Death and long-term disability from COVID-19 due largely to body's hyper-inflammatory response to the virus and the damage it is causing
- This inappropriate response associated with excessive production of pro-inflammatory molecules (cytokines) in lungs
- One of the anti-cancer effects of Veyonda® requires blocking production of pro-inflammatory cytokines (STING pathway)
- The NOXCOVID study is the first test of the hypothesised benefit of blocking STING in COVID-19

5. Investment Case



DARRT

Estimated **300,000 deaths globally**; 33,000 in the U.S.

Focus on **end-stage prostate cancer**

Aiming to make Veyonda standard of care with radiotherapy in end-stage prostate cancer

IONIC

Checkpoint inhibitor 2019 sales = **A$30 billion**

Potential market estimated **>A$150 billion p.a.**

Aiming to make Veyonda the go-to drug to increase response rates to immune checkpoint inhibitors both in responsive cancers (melanoma, lung, bladder etc) **and poorly responsive cancers** (breast, ovarian, prostate, bowel, sarcoma etc)

5. Investment Case

Prostate cancer in particular is major area of M&A activity

	XTANDI® mCRPC (201^)	^{177}Lu-PSMA-617 mCRPC (2018)	^{177}Lu-PSMA-617 and others mCRPC (2018)
Buyer	Pfizer	NOVARTIS	NOVARTIS
Seller	MEDIVATION	ENDOCYTE	Advanced Accelerator Applications
Price Range	US$14 billion	US$2.1 billion	US$3.9 billion

5. Investment Case

Competitive COLD to HOT Technologies

Three main technologies under development:

	Mode	*Examples*
Oncolytic viruses	Viruses that preferentially infect cancer cells to activate an immune response within the tumour	Oncolytics Biotech Inc Phase 2; ASX-listed Viralytics Ltd acquired for $500M by Merck in 2018 after Phase 2.
STING agonists	Drugs designed to activate an immune response within tumours	Oncosec Medical Inc Phase 2; Idera Pharmaceuticals Phase 2
Radiotherapy	Using radiation to trigger immune activation.	

Advantages of Veyonda

- Pre-clinical data confirming ability to activate T-cells (CD4+ and CD8+) and to increase T-cell trafficking into tumours
- Well-tolerated with no D ose-Limiting Toxicity
- Molecular target common to all known human cancer types, suggesting broad use
- Self-administered, cost-effective treatment

5. Investment Case

Multiple programs = multiple catalysts Q3 20 – Q2 21



5. Investment Case

3 key investment questions

Is there a need for Veyonda®, and if so, how large is the commercial opportunity?	What evidence is there that Veyonda® is capable of delivering on its promise?	What will it mean to me as a shareholder if Veyonda® succeeds?
Better palliative care for end-stage cancer is one of the single largest unmet pharma needs in the world with an estimated value > **A$100 billion p.a.**	Pre-clinical and Phase 1 clinical data point to Veyonda being a first-in-class converter of COLD to HOT tumours, a fundamental step in I-0 Rx	NOX believes either: (i) improving response rates to immune checkpoint inhibitors (IONIC), or (ii) providing better palliative care for end-stage cancer patients (DARRT) is certain to position Veyonda® as an important new drug with 'blockbuster' deal potential

Senior Management Team

Dr Graham Kelly CEO
& Managing Director



Fred Bart
Non-Exec Chairman

Dr Gisela Mautner
Chief Medical Officer

Jeanette Bell
Chief Operating Officer

Key Metrics

Number of Shares	**213.2 million shares outstanding**
Board shareholding	**19.8%**
Share price	**A$0.39** (18 Sept 2020)
Listing date	**9 August 2016**
Market cap	**A$83 M** (18 Sept 2020)
Cash position	**AU$ 7.1 M** (30 June 2020)

Discover Develop Deliver

NOXOPHARM

A second generation I-O therapy to transform the management of cancer

www.noxopharm.com

Email: info@noxopharm.com
Phone: (+61) 2 9144 2223

https://www.linkedin.com/company/noxopharm-limited

https://twitter.com/noxopharm

Media Enquiries
The Capital Network
Julia Maguire
+61 2 8999 3699
julia@thecapitalnetwork.com.au